Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Universal Insurance Holdings (UVE) despite lower revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - Universal Insurance is expected to report quarterly earnings of $1.30 per share, reflecting a significant year-over-year increase of +420% [3]. - Revenues are projected to be $372.99 million, which is a decrease of 3.1% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate for Universal Insurance matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of actual earnings deviating from consensus estimates, with a positive ESP being a strong predictor of an earnings beat [8][9]. - Universal Insurance's current Zacks Rank is 3 (Hold), which complicates the prediction of an earnings beat [11][12]. Historical Performance - In the last reported quarter, Universal Insurance exceeded the expected earnings of $1.1 per share by delivering $1.36, resulting in a surprise of +23.64% [13]. - The company has successfully beaten consensus EPS estimates in each of the last four quarters [14]. Market Sentiment - An earnings beat or miss may not solely dictate stock movement, as other factors can influence investor sentiment [15]. - Despite not appearing as a compelling earnings-beat candidate, other factors should be considered when evaluating the stock ahead of its earnings release [17]. Industry Comparison - Skyward Specialty Insurance (SKWD), another player in the property and casualty insurance sector, is expected to report earnings of $0.93 per share, reflecting a year-over-year increase of +16.3% [18]. - Skyward's revenues are anticipated to be $374 million, up 22.9% from the previous year, with a positive Earnings ESP of +0.86% indicating a likely earnings beat [19][20].

Core Viewpoint - Wall Street anticipates a year-over-year decline in Westlake's earnings due to lower revenues, with a consensus estimate of a quarterly loss of $1.33 per share, reflecting a significant change of -2316.7% compared to the previous year [1][3]. Earnings Expectations - Revenues for Westlake are projected to be $2.57 billion, which is a decrease of 9.7% from the same quarter last year [3]. - The stock price may increase if the actual earnings exceed expectations in the upcoming report, scheduled for February 24 [2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not reassessed their initial estimates during this period [4]. - Westlake's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.58%, suggesting a bearish outlook from analysts [12]. Earnings Surprise History - In the last reported quarter, Westlake was expected to post earnings of $0.18 per share but instead reported a loss of -$0.29, resulting in a surprise of -261.11% [13]. - The company has not beaten consensus EPS estimates in any of the last four quarters [14]. Investment Considerations - Despite the potential for an earnings beat, other factors may influence stock movement, and a positive earnings surprise does not guarantee a stock price increase [15]. - Westlake is not currently viewed as a compelling candidate for an earnings beat, and investors should consider additional factors before making investment decisions [17].

Core Viewpoint - Apellis Pharmaceuticals, Inc. (APLS) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ending December 2025, with a consensus outlook indicating a potential impact on its near-term stock price [1]. Financial Performance Expectations - The upcoming earnings report is expected to be released on February 24, and if the results exceed expectations, the stock may rise; conversely, missing estimates could lead to a decline [2]. - The consensus estimate predicts a quarterly loss of $0.39 per share, reflecting a year-over-year change of -34.5%, with revenues projected at $194.37 million, down 8.5% from the previous year [3]. Estimate Revisions Trend - Over the last 30 days, the consensus EPS estimate has been revised 0.84% higher, indicating a reassessment by covering analysts [4]. - The Most Accurate Estimate for Apellis is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -3.07%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, with a positive ESP being a strong predictor of an earnings beat [9][10]. - Apellis currently holds a Zacks Rank of 3, which complicates the prediction of an earnings beat given the negative Earnings ESP [12]. Historical Performance - In the last reported quarter, Apellis was expected to post earnings of $1.03 per share but delivered $1.67, resulting in a surprise of +62.14% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Comparison - In contrast, Axsome Therapeutics (AXSM), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $0.7 per share for the same quarter, with revenues projected to be $193.01 million, up 62.5% year-over-year [18]. - Axsome's consensus EPS estimate has been revised 9.2% higher in the last 30 days, resulting in a positive Earnings ESP of +43.57%, suggesting a likely earnings beat [19][20].

Solaris Energy Infrastructure, Inc. (SEI) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 24, might help the stock move higher if these key numb ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Carlyle Secured Lending, Inc. (CGBD) despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.38 per share, reflecting a year-over-year decrease of 19.2%, while revenues are projected to be $45.58 million, an increase of 16.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial projections [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Carlyle Secured Lending is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.60%, suggesting a bearish outlook from analysts [11]. Historical Performance - In the last reported quarter, Carlyle Secured Lending was expected to post earnings of $0.39 per share but delivered $0.38, resulting in a surprise of -2.56%. Over the last four quarters, the company has only beaten consensus EPS estimates once [12][13]. Investment Considerations - While the company does not appear to be a strong candidate for an earnings beat, investors should consider other factors influencing stock performance beyond earnings results [16].

Wall Street expects a year-over-year increase in earnings on higher revenues when CoStar Group (CSGP) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February ...

Core Viewpoint - Cytokinetics (CYTK) is anticipated to report a year-over-year decline in earnings due to lower revenues, with a consensus outlook indicating a quarterly loss of $1.48 per share, representing a 17.5% decrease from the previous year, and revenues expected to be $3.89 million, down 77% from the same quarter last year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 24, and the stock may rise if the reported numbers exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 1.25% lower in the last 30 days, reflecting a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Cytokinetics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.95%, suggesting a bearish outlook from analysts [11]. - The stock currently holds a Zacks Rank of 3, making it challenging to predict a beat on the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Cytokinetics was expected to post a loss of $1.59 per share but actually reported a loss of -$1.54, resulting in a positive surprise of +3.14% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Conclusion - While Cytokinetics does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].

Core Insights - Amazon.com, Inc. (AMZN) has experienced a significant decline, with shares falling for nine consecutive sessions, marking one of the longest losing streaks in nearly two decades [1][4][7] - The decline is part of a broader trend affecting large-cap tech stocks, particularly in the tech-heavy Nasdaq, as investors reassess valuations and growth expectations related to the artificial intelligence (AI) sector [2][3][7] Company Performance - Since February 2, 2023, AMZN's stock has dropped 18.2%, underperforming its sub-industry, which has decreased by 15.9%, and peers such as Alibaba Group Holding Limited (BABA) and 1stdibs.Com, Inc. (DIBS), which fell by 7.5% and 3.3%, respectively [6][7] - Amazon's cloud division plays a crucial role in AI development, making the stock particularly sensitive to shifts in investor sentiment regarding AI-related investments [3][5] Market Sentiment - The current downturn reflects a broader macroeconomic and sector-driven sentiment shift rather than specific issues within Amazon, highlighting the volatility that can occur in richly valued market segments [4][5] - As risk appetite diminishes, traders are reducing their positions in major technology companies, including Amazon, indicating a cautious approach to high-growth stocks [2][3]

Core Insights - JPMorgan's loan book accelerated in Q4 2025, with significant growth in wholesale lending and credit cards, indicating a strategic focus on areas where the bank has scale advantages [1][2] Loan Growth and Composition - As of December 31, 2025, total loans reached $1.49 trillion, reflecting a 4% sequential increase and an 11% year-over-year growth, driven primarily by wholesale loans which rose 5% quarter-over-quarter and 17% year-over-year to $843.4 billion [2][9] - Within the consumer loan segment, credit card loans showed the strongest growth, increasing 5% sequentially and 6% year-over-year to $247.8 billion, while other consumer loans (excluding cards) grew modestly by 2% to $402.3 billion [3][9] Strategic Partnerships - In January 2026, JPMorgan signed an agreement to become the new issuer of Apple Card, which is expected to add approximately $20 billion in card balances to Chase, enhancing JPMorgan's presence in the U.S. card market [4] Interest Income and Projections - A lower interest rate environment is anticipated to boost borrowing and refinancing, supporting loan growth despite potential pressure on net interest income (NII). JPMorgan expects NII to reach approximately $103 billion in 2026, a 7.4% increase from $95.9 billion in 2025 [5] Peer Comparison - As of December 31, 2025, Bank of America reported total loans and leases of $1.17 trillion, up 8% year-over-year, with commercial loans growing 12% [6] - Citigroup's loans totaled $752 billion, with corporate loans growing 14% year-over-year, while consumer loans increased by 4% [7] Valuation and Earnings Estimates - JPMorgan shares have appreciated by 3.8% over the past six months, and the bank trades at a price-to-tangible book (P/TB) ratio of 2.98X, below the industry average [8][10] - The Zacks Consensus Estimate projects a 5.1% increase in JPMorgan's earnings for 2026, with a further growth rate of 7.6% expected for 2027 [11]

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence through various research services [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, serving as complementary indicators to the Zacks Rank [3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperforming the market [4] Value Score - The Value Style Score focuses on identifying undervalued stocks by analyzing financial ratios such as P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings estimate changes to identify favorable buying opportunities [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking attractive value, growth, and momentum [7] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to assist investors in building successful portfolios [8] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +23.86% since 1988, significantly outperforming the S&P 500 [9] Stock Recommendation: Air Products and Chemicals (APD) - Air Products and Chemicals Inc. is rated 2 (Buy) on the Zacks Rank with a VGM Score of A, making it a notable option for momentum investors [12] - The stock has seen a 4.6% increase over the past four weeks, supported by positive earnings estimate revisions [12][13] - The Zacks Consensus Estimate for fiscal 2026 has risen by $0.05 to $13.01 per share, with an average earnings surprise of +0.4% [13]